摘要
目的 分析替吉奥联合胃肿瘤血管介入栓塞用于中老年晚期胃癌治疗的临床疗效及安全性。方法 选定2024年2月至2026年3月于我院被收治的30例中老年晚期胃癌患者，随机分成对照组、观察组，每一组15例，对照组给予单药替吉奥口服给药治疗，观察组联合胃肿瘤血管介入栓塞这一方案，比较两组临床疗效、血清肿瘤相关标志物、生存质量和不良反应表现。结果 观察组疾病控制率以及生存质量改善率均高于对照组，对照组癌胚抗原、糖类抗原125水平比观察组高（P<0.05）；两组不良反应发生率无统计学方面的差异（P>0.05）。结论 替吉奥与介入栓塞联合有助于提高中老年晚期胃癌治疗效果，改进患者生活质量，且其安全性是可靠的。
关键词： 替吉奥；胃肿瘤血管介入栓塞；中老年晚期胃癌；血清肿瘤标志物；生存质量
Abstract
Objective To analyze the clinical efficacy and safety of S-1 combined with gastric tumor vascular embolization in the treatment of middle-aged and elderly patients with advanced gastric cancer. Methods 30 middle-aged and elderly patients with advanced gastric cancer admitted to our hospital from February 2024 to March 2026 were selected and randomly divided into control group and observation group, with 15 cases in each group. The control group was treated with single drug S-1 orally, and the observation group was treated with gastric tumor vascular interventional embolization. The clinical efficacy, serum tumor related markers, quality of life and adverse reactions of the two groups were compared. Results the disease control rate and the improvement rate of quality of life in the observation group were higher than those in the control group, and the levels of carcinoembryonic antigen and carbohydrate antigen 125 in the control group were higher than those in the observation group (p<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (p>0.05). Conclusion S-1 combined with interventional embolization can improve the treatment effect and quality of life of elderly patients with advanced gastric cancer, and its safety is reliable.
Key words： S-1; Interventional embolization of gastric tumor vessels; Middle aged and elderly patients with advanced gastric cancer; Serum tumor markers; Quality of life
参考文献 References
[1] 李书有,聂荣军,苏凤婵,等.替吉奥联合胃肿瘤血管介入栓塞治疗中老年晚期胃癌的临床研究[J].智慧健康, 2024, 10(3):184-187.
[2] 陈秀峰,沈玲.替吉奥联合胃肿瘤血管介入栓塞治疗中老年晚期胃癌的临床研究[J].智慧健康, 2025, 11(8):94-97.
[3] 张兰芳,陈旭,蒯君,等.替吉奥联合奥沙利铂对老年胃癌患者胃动力相关激素及基质金属蛋白酶-2,基质金属蛋白酶-9的影响[J].实用临床医药杂志, 2024, 28(12):57-60,65.
[4] 刘政宏,高佳.阿帕替尼联合化疗对晚期胃癌患者血清学指标及疗效的影响分析[J].现代医学与健康研究电子杂志, 2024(003):008.
[5] 兰峰,孙静,张永辉,等.奥沙利铂联合替吉奥治疗对进展期食管癌患者生存时间的影响[J].贵州医科大学学报, 2023, 48(10):1204-1208.
[6] 汪秀梅,王康康,徐霞,等.替吉奥及奥沙利铂联合治疗晚期胃癌的临床观察[J].实用癌症杂志, 2025, 40(10):1660-1663.
[7] 孙灿朝.槐耳颗粒联合奥沙利铂和替吉奥治疗中晚期胃癌的临床疗效观察[J].健康时尚, 2025(5):106-108.
[8] 王立钢,徐道静.中晚期胃癌患者施行奥沙利铂联合替吉奥治疗的临床效果[J].健康忠告, 2025(15):22-24.